Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Charles Lapp

Internal Medicine Charlotte, NC Medical Doctor

NPI 1588778534 CMS profile 26319

7421 Carmel Executive Park Dr, Suite 320, Charlotte, NC 28226

Open in the dashboard

General payments

$2,958

164 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Charles Lapp of Charlotte, NC is reported in the CMS Open Payments database as having received $2,958 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $74 4
2023 General $674 36
2022 General $648 34
2021 General $836 49
2020 General $352 19
2019 General $374 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Lapp
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Charles Lapp were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Charles Lapp Internal Medicine median Middle half National median
2019 $374 $159 $48–$570 $163
2020 $352 $119 $33–$402 $114
2021 $836 $135 $37–$521 $132
2022 $648 $141 $42–$496 $149
2023 $674 $149 $45–$519 $160
2024 $74 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $416 24 payments
  2. Biohaven Pharmaceuticals, Inc. $374 18 payments
  3. Pfizer Inc. $286 15 payments
  4. Bausch Health US, LLC $254 17 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $252 13 payments
  6. Lilly USA, LLC $188 8 payments
  7. Biodelivery Sciences International, Inc. $109 7 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $102 6 payments
  9. Amgen Inc. $94 5 payments
  10. Collegium Pharmaceutical, Inc. $91 5 payments
  11. Other $793 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,958 164 payments
Products named General payments · program years 2019–2024
  1. NURTEC ODT Primary Care $626 31 payments
  2. NURTEC ODT Pain $241 13 payments
  3. APLENZIN $238 16 payments
  4. WELLBUTRIN $213 15 payments
  5. UBRELVY $211 13 payments
  6. QULIPTA $186 8 payments
  7. PAXLOVID $135 7 payments
  8. ZAVZPRET $127 7 payments
  9. AIMOVIG $114 6 payments
  10. XIFAXAN $102 6 payments
  11. Other $1,934 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

244

Median for Internal Medicine: 777

Drug cost

$3,590

Median for Internal Medicine: $73,373

Branded share of claims

4.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clonazepam Generic 60 $635
Gabapentin Generic 31 $580
Fludrocortisone Acetate Generic 15 $428
Carisoprodol Generic 12 $381
Duloxetine Hcl Generic 11 $360
Tizanidine Hcl Generic 14 $242
Trazodone Hcl Generic 25 $207
Bupropion Hcl Sr Bupropion Hcl Brand 12 $201
Topiramate Generic 12 $158
Lorazepam Generic 11 $139

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $21
$21 — —
NURTEC ODT
  • PFIZER INC. $19
$19 — —
ZAVZPRET
  • PFIZER INC. $19
$19 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $8
$8 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record